Off-label use of targeted therapies in oncology - Wikidata - awgldk - TriplyDB

Off-label use of targeted therapies in oncology

Off-label use of targeted therapies in oncology

http://www.wikidata.org/entity/Q26747685

about

Data resources for the identification and interpretation of actionable mutations by clinicians.Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.

P2860

Q36317783-9A140A17-ACDA-4544-AC01-7342948A8EBD Q50001044-E750C04B-5CF9-410B-8E09-88411F62D4E5

P2860

Off-label use of targeted therapies in oncology

http://www.wikidata.org/entity/Q26747685

description

2016 nî lūn-bûn

@nan

2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Off-label use of targeted therapies in oncology

@ast

Off-label use of targeted therapies in oncology

@en

Off-label use of targeted therapies in oncology

@nl

type

label

Off-label use of targeted therapies in oncology

@ast

Off-label use of targeted therapies in oncology

@en

Off-label use of targeted therapies in oncology

@nl

prefLabel

Off-label use of targeted therapies in oncology

@ast

Off-label use of targeted therapies in oncology

@en

Off-label use of targeted therapies in oncology

@nl

P1433

Q26747685-29456423-EBF2-475B-9698-8375641AEDDD

P1476

Q26747685-08AEEC17-D5BE-4210-9D33-C31EB624BE38

P2093

Q26747685-0305C168-0F5C-40C2-8A01-870E0CAA6B43

P2860

Q26747685-1D6FCAFF-F471-4CD6-9B8A-59A06FC3A13E

Q26747685-23DB750C-AE58-4B99-8D6F-632CB8C2701F

Q26747685-2667A87F-9F8B-4F95-B0B9-00DF4105A3E6

Q26747685-2D144234-3CD6-4504-A810-9B1404104B15

Q26747685-2FB17F07-27A2-45CA-A531-9C3FEDE2B797

Q26747685-3F492746-E733-41D3-833E-A04A35747AE4

Q26747685-45EF0EAC-EF0D-4457-99DB-BC34AFE7850F

Q26747685-4EC5182C-8837-47DE-900C-97F741B7E274

Q26747685-56992FB3-2E21-4C70-AF51-79E395718734

Q26747685-59E51F00-72D0-4AEB-81D0-AA300A2A269A

P304

Q26747685-5FCD8DEE-F25E-43C0-9CC6-17EB25D20351

P31

Q26747685-BDAA9534-9948-4B5C-A5DD-1AE56CCECF1A

P356

Q26747685-0AEACCE2-CA8F-45B2-9BB3-78B86A22501B

P407

Q26747685-7A34AB72-5256-4D28-8FF1-BABE9801E1DB

P433

Q26747685-832025D5-D8B4-48E3-AD7D-19B0B5771E3F

P478

Q26747685-523637A3-D93A-469B-8743-62F68EA6F1DD

P577

Q26747685-DC76942C-CB8A-418E-B33F-E0256A93087F

P698

Q26747685-4A58AB83-56A8-4AB5-9F87-5D934EF5CC77

P932

Q26747685-FBB94FE6-A1D6-4A6A-B80A-7211AC2D0838

P356

P1433

World journal of clinical oncology

P1476

Off-label use of targeted therapies in oncology

@en

P2093

Dominique Levêque

http://www.w3.org/2001/XMLSchema#string

P2860

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Hepatotoxicity with combination of vemurafenib and ipilimumab

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Comprehensive analysis of kinase inhibitor selectivity

Prospective Clinical Study of Precision Oncology in Solid Tumors.

Prospective data collection of off-label use of rituximab in Australian public hospitals.

Outcomes of off-label drug uses in hospitals: a multicentric prospective study

Unsupported off-label chemotherapy in metastatic colon cancer.

Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience

P304

253-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5306/WJCO.V7.I2.253

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27081648

http://www.w3.org/2001/XMLSchema#string

P932

4826971

http://www.w3.org/2001/XMLSchema#string